Sirolimus
Disease Related To Solid Organ Transplantation
Explore 18 assets in Disease Related To Solid Organ Transplantation →Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Melanoma and Skin Cancer Trials Limited
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05860881CT.gov Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin) | — | Active Not Recruiting | — | — | — |
NCT03500848CT.gov Sirolimus-based Immunosuppression Treatment Regimen for Liver Transplantation | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Disease Related To Solid Organ Transplantation
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sirolimus (this asset) | Melanoma and Skin Cancer Trials Limited | P3 | BB · 64 |
| Tacrolimus | The Second Hospital of Tangshan | P4 | BBB |
| Angiotensin Ii | University of California, San Francisco | P4 | BBB |
| Equine Atg | University Hospital, Toulouse | P4 | BB |
| Everolimus | Novartis Pharmaceuticals | P3 | BB |
| Envarsus Product | University of Alberta | P4 | BB |
| Sitagliptin | University Health Network, Toronto | P4 | BB |
| Noradrenaline | University of California, Los Angeles | P4 | BB |
| Semaglutide | University Health Network, Toronto | P4 | BB |
+26 more in the Disease Related To Solid Organ Transplantation cohort
Other indications for Sirolimus
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Tuberous Sclerosis | — | P3 | BBB · 73 |
| Disease Related To Transplantation | — | P4 | BBB · 72 |
| Myelodysplastic/Myeloproliferative Neoplasm | — | P2 | BB · 69 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sirolimus in Disease Related To Solid Organ Transplantation. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sirolimus-disease-related-to-solid-organ-transplantation
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →